Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Centre for Rehabilitation Research in Oxford (RRIO) led by Professor Sallie Lamb of NDORMS has been awarded £2 million by the National Institute for Health Research (NIHR) to look at improving the management of lower back pain in older people.

The Centre for Rehabilitation Research in Oxford (RRIO) lead by Professor Sallie Lamb of NDORMS has been awarded £2 million by the National Institute for Health Research (NIHR) to look at improving the management of lower back pain in older people.

Lower back pain is now recognised as the leading disabling condition in the world, with over 70% of people suffering with it in their lifetime. Older people in particular are at higher risk of having the most serious forms of lower back pain, leading to mobility decline and falls, as well as frailty and loss of independence – a key concern for this age group.

Despite this, lower back pain in older people is often ignored, missed or mismanaged in primary care. Both patients and their GPs may dismiss treatment for lower back pain, instead accepting it as part of ageing and prioritising the treatment of other health conditions. In addition, although there is a large amount of research on back pain, older people are often excluded from these studies.

The BOOST programme of research (Better Outcomes for Older People with Spinal Trouble) will help primary health care clinicians, patients and their carers recognise when to prioritize the treatment of back pain , and to explore and hopefully counter prejudices held by older people and clinicians.  It will also evaluate a physiotherapy programme for people with neurogenic claudication, a condition arising from ageing changes within the spine, which is common in older people and can severely limit their ability to walk and stand.  

Dr Esther Williamson, NDORMS Research Fellow and project lead says: "Remaining independent is the key concern for older people. Through this work we want to develop evidence based treatment strategies as well as an improved understanding of prognosis and greater knowledge about back pain in older people. By developing effective treatments we hope to reduce pain but also have an impact on broader health outcomes, helping older people to remain active and independent and preventing falls and frailty."

If you’d like to find out more about this study or be involved, please contact Esther and the BOOST research team at BOOST@ndorms.ox.ac.uk

 

Similar stories

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Sara Khalid named Associate Professor at NDORMS

The University of Oxford has awarded the title of Associate Professor to Dr Sara Khalid as part of its recognition of excellence awards.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.